Placebos are at heart of clinical-trial changes

04/21/2013 | PharmaLive.com

Tighter restrictions on the use of placebos, more protections for vulnerable populations, and compensation and treatment for individuals harmed in clinical trials are among the recent draft changes made by the World Medical Association to the Helsinki Declaration on medical research. Among the changes are provisions saying that researchers can use placebos only when no other reasonable option is available and they can target vulnerable patient groups only when they are unable to employ non-vulnerable populations.

View Full Article in:

PharmaLive.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD